Research
Hormonal
Tirzepatide (5-15 mg weekly) achieves mean weight loss of 15-21% in adults with BMI ≥27 kg/m², demonstrating superior efficacy compared to placebo and potentially other GLP-1 agonists.
Tirzepatide is a weekly injection available in doses up to 15mg. It can help you lose over 20% of your body weight if you have a BMI over 27. Side effects like nausea are common but often manageable. It is approved for obesity management in the US and UK.
StrongSupportsVERY_HIGH confidence
In individuals with BMI (cid:1)27 kg/m2 without T2D, mean (95% confidence interval) percentage change in weight with tirzepatide 5, 10 and 15 mg over 72 weeks was (cid:3)15.0% ((cid:3)14.2 to (cid:3)15.9), (cid:3)19.5% ((cid:3)20.4 to (cid:3)18.5) and (cid:3)20.9% ((cid:3)19.9 to (cid:3)21.8) compared to(cid:3)3.1 ((cid:3)4.3 to (cid:3)1.9) with placebo
Why this rating
Based on Phase 3 RCT (SURMOUNT 1) with N=2539.
Source
Obesity medications: A narrative review of current and emerging agents
Qi Q et al. · Osteoarthritis and Cartilage Open · 2024
narrative_reviewCited 20×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →